A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study With an Open-Label Extension to Determine the Safety, Pharmacokinetics and Efficacy of Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 24 Oct 2018
At a glance
- Drugs Ifetroban (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions
- Sponsors Cumberland Pharmaceuticals
- 15 Oct 2018 Planned End Date changed from 1 Nov 2021 to 1 Dec 2021.
- 15 Oct 2018 Planned primary completion date changed from 1 Nov 2021 to 1 Dec 2021.
- 15 Oct 2018 Planned initiation date changed from 1 Nov 2018 to 1 Feb 2019.